

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

OVISE

RRID:CVCL_3116

Type: Cell Line

Proper Citation

RRID:CVCL_3116

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3116

Proper Citation: RRID:CVCL_3116

Description: Cell line OVISE is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian clear cell adenocarcinoma

Defining Citation: [PMID:7535723](#), [PMID:9328139](#), [PMID:11121861](#), [PMID:15677628](#), [PMID:17671176](#), [PMID:20081105](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22705003](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26388441](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVISE

Cross References: BTO:BTO_0003498, CLO:CLO_0037097, EFO:EFO_0006724, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:983, BioSample:SAMN02800475, BioSample:SAMN03472858, BioSample:SAMN10988266, cancercellines:CVCL_3116, Cell_Model_Passport:SIDM00564, CGH-DB:330-2, Cosmic:1223316, Cosmic:1328065,

Cosmic:1434893, Cosmic:1708377, Cosmic:1995606, Cosmic:2074246, Cosmic:2482699, Cosmic-CLP:1240198, DepMap:ACH-000527, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240198, GEO:GSM416678, GEO:GSM659395, GEO:GSM827222, GEO:GSM888567, GEO:GSM1176280, GEO:GSM1670321, IARC_TP53:30140, JCRB:JCRB1043, JCRB:NIHS0296, JCRB:NIHS0338, LiGeA:CCLE_251, LINCS_LDP:LCL-1524, PharmacDB:OVISE_1222_2019, PRIDE:PXD000901, PRIDE:PXD003105, PRIDE:PXD003668, PRIDE:PXD030304, Progenetix:CVCL_3116, Wikidata:Q54937026

ID: CVCL_3116

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260829T235525+0000

Ratings and Alerts

No rating or validation information has been found for OVISE.

Warning: Discontinued: JCRB; NIHS0296

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: JCRB; NIHS0338

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Tan GYT, et al. (2026) BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). *EMBO molecular medicine*, 18(5), 1933.

Hayashi M, et al. (2025) Prognostic Significance of S100A4 in Ovarian Clear Cell Carcinoma: Its Relation to Tumor Progression and Chemoresistance. *Cancers*, 17(2).

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. *Cancer research*, 85(18), 3471.

Little S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. *iScience*, 28(6), 112555.

Xu Y, et al. (2023) Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. *Cell reports*, 42(10), 113307.

Zhou W, et al. (2023) Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. *Cancer cell*, 41(4), 740.

Nakagawa M, et al. (2023) Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma. *Molecular oncology*, 17(10), 2168.

Ferrari AJ, et al. (2023) H2Bub1 loss is an early contributor to clear cell ovarian cancer progression. *JCI insight*, 8(12).

Brubaker LW, et al. (2023) Novel chromobox 2 inhibitory peptide decreases tumor progression. *Expert opinion on therapeutic targets*, 1.

Tsuchimochi S, et al. (2023) Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma. *Scientific reports*, 13(1), 20292.

Zundell JA, et al. (2021) Targeting the IRE1 α /XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. *Cancer research*, 81(20), 5325.

Neggers JE, et al. (2020) Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. *Cell reports*, 33(11), 108493.